

March 3, 2021

**Formulation of MISSION, VISION 30 and  
Medium-Term Management Plan 21–25  
-Creating hope for all facing illness.-**

- We have formulated MISSION and VISION 30 that describe our purpose and vision for 2030 as we work to address future social issues
- We have also formulated Medium-Term Management Plan 21–25 that covers the first five years in our efforts to achieve VISION 30
- We will develop precision medicine and around the pill solutions to achieve VISION 30

Mitsubishi Tanabe Pharma Corporation (MTPC, Head Office : Osaka; President & Representative Director : Hiroaki Ueno) announced the formulation of the Company's MISSION to replace our Philosophy and VISION 30 as our Vision for 2030, having reflected on what MTPC has accomplished to date and re-examined how MTPC should be in society in light of the future outlook for healthcare. In order to lay the foundations for achieving VISION 30, we have also formulated our Medium-Term Management Plan 21–25 covering the period up to fiscal 2025.

## **1. Formulation of MISSION and VISION 30**

### **(1) MISSION: Creating hope for all facing illness.**

Since the Company was founded over 300 years ago, MTPC's strengths and purpose have been to eliminate incurability, as well as drug discovery and proposal capabilities creating treatment choices that "creating hope". In light of the anticipated changes in healthcare needs in the future, we will enter a new era when people facing illness have hopes beyond conventional "medicine." Given MTPC's strengths plus this outlook for healthcare, we have concluded that our new MISSION is to create treatment choices that bring new hope, both for those who are facing illness today and those who may face illness in the future. MTPC will be guided by this new MISSION as we pursue our business activities.

### **(2) VISION 30: Be a healthcare company that delivers optimal therapy to each individual.**

When considering our MISSION, we decided that by 2030 healthcare will expand beyond hospitals and into private homes, and will require total care that encompasses daily activities and emphasizes the satisfaction of patients and their

families. Under VISION 30, MTPC provide therapeutic agents and wide-ranging solutions designed with the patient and their family in mind. We see three key areas where we provide value:

- We provide highly effective treatment to specific patient groups and increase patient satisfaction with detailed analysis of the disease.
- We provide solutions focused on prevention, pre-symptomatic disease care, prevention of aggravation and prognosis.
- We continue improving the value of our therapeutics and solutions by collecting and analyzing healthcare data.

We expect our newly defined MISSION and VISION 30 to help us to realize the KAITEKI strategy of the Mitsubishi Chemical Holdings Corporation Group.

### **KAITEKI Value for Tomorrow**

**Imagine the future. Change for tomorrow.**

Imagine our future. How do we get there - to a sustainable future?  
KAITEKI - the sustainable well-being of people, society and our planet Earth.  
For our future, the Mitsubishi Chemical Holdings Corporation (MCHC) Group will bring solutions for tomorrow.

As the core company responsible for the MCHC Group's healthcare business (PHARMACEUTICAL AND HEALTH), Mitsubishi Tanabe Pharma will contribute to the MCHC Group's Vision "Realizing KAITEKI" by providing "Creating hope for all facing illness."

### **MISSION**

**Creating hope for all facing illness.**

### **VISION 30**

**Be a healthcare company that delivers optimal therapy to each individual.**

## **2. Outline of Growth Strategy for 2030 — Precision Medicine and Around the Pill Solutions —**

The outline of growth strategy to achieve VISION 30 is based on precision medicine and around the pill solutions. Under the precision medicine category, we will identify in advance the best candidate patient groups in terms of both efficacy and safety, and will provide effective treatments for these patient groups and increase patient satisfaction. As well as treatment, we will also develop around the pill solutions to address specific patient concerns based on therapeutic medicine, including prevention and pre-symptomatic disease care, prevention of aggravation, and prognosis. In this way, we will contribute to improving the quality of life of patients and their families. Through these two approaches, we will collect and analyze healthcare data to continue improving the value of our therapeutics and solutions, with the goal of building up our strengths to become a recognized name in central nervous system, immuno-inflammation, and other domains.

### **3. Medium-Term Management Plan 21–25**

Basic Strategies: Focus on the three perspectives of research and development, business development, and management base in order to lay the foundation for growth strategies during the transformation period toward VISION 30.

Duration: April 2021–March 2026 (five years)

#### **Research & Development**

<Realize precision medicine focused on central nervous system and immuno-inflammation treatments. Focused on vaccines area and contribute to preventive medicine.>

- In the central nervous system area, we will use our abundant expertise and information on amyotrophic lateral sclerosis (ALS), obtained through Radicava research and development, to help quickly identify disease genes and pursue new modalities for intractable neurological diseases with shared pathophysiological processes. We will also work to develop designed pharmaceuticals (agents that combine pharmaceuticals and devices), starting with ND0612 for Parkinson’s disease.
- In the immuno-inflammation area, we will pursue phenotypic drug discovery for patient groups with diseases presenting various pathological conditions and with no current effective treatment agent, with a focus on systemic sclerosis and systemic lupus erythematosus.
- In the vaccine area, we will contribute to efforts to prevent infectious diseases, including the Japanese launch with the BIKEN Group of MT-2355 (5 combined vaccine) and development of Medicago’s VLP vaccine to prevent COVID-19 that is affecting societies at present.

#### **Business Development**

<Strengthen business in the U.S. and Japan, and develop around the pill solutions to create new customer contact points>

- We position the U.S. as a region with growth potential and will strengthen our business base and create new customer contact points through strategies to maximize the value of Radicava/MT-1186 and MT-7117 (Dersimelagon) and the provision of around the pill solutions. We are also preparing for the launch of ND0612, with the goal of establishing this product as a growth driver.
- In Japan, we will deepen our current businesses in the priority disease areas of Diabetes and kidney, Immuno-inflammation, Central nervous

system, and Vaccine, and also broaden our operational scope to develop new business foundations in order to maintain Japan as the mother market. We will work to maximize product value for priority products and for six products under development scheduled for launch.

- We will introduce products launched in the U.S. and Japan to China and Asia and maximize the value of our global products. We will also streamline businesses to boost profitability and create strong business foundations.

### **Management Base**

<Create a resilient organization and optimize the allocation of management resources for achieving VISION 30>

- For organizational and human resources reforms, we will promote the specialty, diversity, and digitization of organizations and people towards innovation.
- We will also form strategic introduction and alliances aimed at strengthening our business and will develop various investments to acquire drug discovery and digital technologies.
- We will build a digital infrastructure and advance digital transformation to support the VISION 30 growth strategies and enhance value chain productivity.

Please refer to the materials on Medium-Term Management Plan 21–25 ([link](#)) for more details.

We have made some revisions to the seven material issues designated in 2018 and have also added one new material issue to make a total of eight. We will work to address these material issues in order to realize our MISSION and VISION 30, as well as to advance growth strategies and create hope.

<Eight Material issues>

- |   |   |
|---|---|
| •Innovative pharmaceuticals and healthcare services | •Stakeholder engagement*                  |
| •Quality assurance and stable supply                | •Employee health, diversity and inclusion |
| •Appropriate use of products                        | •Environment-friendly business*           |
| •Access to healthcare*                              | •Ethics, fairness and integrity           |

\* Changed/added from material issues designated in 2018

**Mitsubishi Tanabe Pharma Corporation**  
**Corporate Communications Department**

Media contacts: TEL: +81 6 6205 5119